HK1207067A1 - 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) - Google Patents
3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)Info
- Publication number
- HK1207067A1 HK1207067A1 HK15107642.0A HK15107642A HK1207067A1 HK 1207067 A1 HK1207067 A1 HK 1207067A1 HK 15107642 A HK15107642 A HK 15107642A HK 1207067 A1 HK1207067 A1 HK 1207067A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- 1h4h6h
- pyrrolo
- pyrazole
- amido
- inhibitors
- Prior art date
Links
- 102000003923 Protein Kinase C Human genes 0.000 title 1
- 108090000315 Protein Kinase C Proteins 0.000 title 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91146207P | 2007-04-12 | 2007-04-12 | |
US3551908P | 2008-03-11 | 2008-03-11 | |
US4011508P | 2008-03-27 | 2008-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207067A1 true HK1207067A1 (en) | 2016-01-22 |
Family
ID=39764996
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107642.0A HK1207067A1 (en) | 2007-04-12 | 2010-06-09 | 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) |
HK15107643.9A HK1207068A1 (en) | 2007-04-12 | 2010-06-09 | 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107643.9A HK1207068A1 (en) | 2007-04-12 | 2010-06-09 | 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) |
Country Status (11)
Country | Link |
---|---|
US (2) | US8114871B2 (ru) |
EP (1) | EP2195321B1 (ru) |
JP (1) | JP5404601B2 (ru) |
KR (1) | KR101113387B1 (ru) |
CN (3) | CN104356136A (ru) |
AU (1) | AU2008237660B2 (ru) |
CA (1) | CA2683695C (ru) |
HK (2) | HK1207067A1 (ru) |
IL (1) | IL201104A (ru) |
MX (1) | MX2009010951A (ru) |
WO (1) | WO2008125945A2 (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009010951A (es) | 2007-04-12 | 2009-10-29 | Pfizer | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
US20120283296A1 (en) * | 2009-10-06 | 2012-11-08 | Afraxis, Inc. | Pyrrolopyrazoles for treating cns disorders |
DK2499139T3 (da) | 2009-11-10 | 2014-01-27 | Pfizer | N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
ES2602111T3 (es) | 2010-09-30 | 2017-02-17 | Pfizer Inc | Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona |
AU2011322117B2 (en) | 2010-10-29 | 2015-01-22 | Pfizer Inc. | N1/N2-lactam acetyl-CoA carboxylase inhibitors |
CA2827157A1 (en) | 2011-02-11 | 2012-08-16 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin c inhibitors |
PL2699576T3 (pl) | 2011-04-22 | 2016-05-31 | Pfizer | Pochodne pirazolospiroketonu do zastosowania jako inhibitory karboksylazy acetylo-COA |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013038390A1 (en) * | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
WO2013167403A1 (en) | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN105377852B (zh) * | 2014-05-23 | 2018-08-28 | 深圳明赛瑞霖药业有限公司 | 自身免疫疾病的治疗 |
US10131679B2 (en) | 2014-10-31 | 2018-11-20 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole compound |
JP2017531684A (ja) * | 2014-11-21 | 2017-10-26 | イーライ リリー アンド カンパニー | 腎障害の治療のための1,2−ベンゾチアゾール化合物 |
CA2972239A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
EP3273966B1 (en) | 2015-03-27 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CA2989519C (en) * | 2015-06-15 | 2023-09-26 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
AU2016355303B2 (en) | 2015-11-20 | 2021-10-07 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
EP3484477B1 (en) | 2016-07-14 | 2023-09-13 | Mingsight Pharmaceuticals, Inc. | Treatment of cancer |
US20220002303A1 (en) | 2018-11-14 | 2022-01-06 | Ube Industries, Ltd. | Dihydropyrrolopyrazole derivative |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001287654B2 (en) * | 2000-08-10 | 2006-12-14 | Pfizer Italia S.R.I. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
UA81790C2 (ru) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Замещенные пиролопиразольные производные как ингибиторы киназы |
WO2004080457A1 (en) * | 2003-03-11 | 2004-09-23 | Pharmacia Italia S.P.A. | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
WO2005030776A1 (en) | 2003-09-23 | 2005-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
EP1838718B1 (en) | 2005-01-10 | 2011-06-15 | Pfizer Inc. | Pyrrolopyrazoles, potent kinase inhibitors |
MX2009010951A (es) | 2007-04-12 | 2009-10-29 | Pfizer | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. |
-
2008
- 2008-04-10 MX MX2009010951A patent/MX2009010951A/es active IP Right Grant
- 2008-04-10 US US12/532,051 patent/US8114871B2/en not_active Expired - Fee Related
- 2008-04-10 CN CN201410533054.4A patent/CN104356136A/zh active Pending
- 2008-04-10 WO PCT/IB2008/000862 patent/WO2008125945A2/en active Application Filing
- 2008-04-10 CA CA2683695A patent/CA2683695C/en active Active
- 2008-04-10 EP EP08737405.4A patent/EP2195321B1/en active Active
- 2008-04-10 JP JP2010502601A patent/JP5404601B2/ja active Active
- 2008-04-10 CN CN201410533053.XA patent/CN104370914B/zh active Active
- 2008-04-10 CN CN200880014779A patent/CN101675052A/zh active Pending
- 2008-04-10 KR KR1020097021175A patent/KR101113387B1/ko active IP Right Grant
- 2008-04-10 AU AU2008237660A patent/AU2008237660B2/en active Active
-
2009
- 2009-09-22 IL IL201104A patent/IL201104A/en active IP Right Grant
-
2010
- 2010-06-09 HK HK15107642.0A patent/HK1207067A1/xx unknown
- 2010-06-09 HK HK15107643.9A patent/HK1207068A1/xx unknown
-
2012
- 2012-01-06 US US13/345,528 patent/US8999981B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN101675052A (zh) | 2010-03-17 |
US8999981B2 (en) | 2015-04-07 |
EP2195321A2 (en) | 2010-06-16 |
JP2010523643A (ja) | 2010-07-15 |
KR20090130039A (ko) | 2009-12-17 |
KR101113387B1 (ko) | 2012-04-23 |
AU2008237660B2 (en) | 2011-12-22 |
CA2683695C (en) | 2013-06-18 |
WO2008125945A3 (en) | 2009-03-12 |
WO2008125945A2 (en) | 2008-10-23 |
IL201104A0 (en) | 2010-05-17 |
JP5404601B2 (ja) | 2014-02-05 |
CN104370914A (zh) | 2015-02-25 |
IL201104A (en) | 2017-09-28 |
US8114871B2 (en) | 2012-02-14 |
CA2683695A1 (en) | 2008-10-23 |
US20120108588A1 (en) | 2012-05-03 |
EP2195321B1 (en) | 2016-10-19 |
MX2009010951A (es) | 2009-10-29 |
HK1207068A1 (en) | 2016-01-22 |
CN104370914B (zh) | 2018-09-07 |
AU2008237660A1 (en) | 2008-10-23 |
CN104356136A (zh) | 2015-02-18 |
US20100249128A1 (en) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207068A1 (en) | 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) | |
HK1139130A1 (en) | 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors pkc 3--[34-c]-5(1h4h6h) | |
IL278119B (en) | Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors | |
ZA201002318B (en) | Pyrrolo [2,3-d]pyrimidin derivatives as protein kinase b inhibitors | |
HUS1200009I1 (hu) | Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok | |
ZA201200982B (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
DK1973910T3 (da) | Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer | |
ZA200802690B (en) | Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | |
ZA201105896B (en) | [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors | |
ZA201000627B (en) | 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors | |
ZA200907825B (en) | 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C | |
IL178688A0 (en) | THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS |